CEO: J. Scott Wolchko

Sector: Health Technology

Exchange: NASDAQ

Country: US

Description: Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Key numbers

Market Capitalization:2581623252
Shares Outstanding: 83873400
Float: 81130320
Next Earning Date:2020-08-05
TTm EPS: -1.5737
TTm Dividend Rate:
200 days moving average:25.09
50 days moving average: 33.04
One day percent Change: -1.04

2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,